Nama's AI scorecard currently rates Krystal Biotech Buy (7.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is KRYS's P/E ratio?

Krystal Biotech trades at a trailing price-to-earnings ratio of 40.8.

When does KRYS report earnings?

Krystal Biotech's next scheduled report is on Feb 16, 2027. Analysts expect EPS of $2.30.

What is the KRYS price target?

The median analyst price target from 9 analysts is $380.00, with a range of $284.00 – $474.00.

Is KRYS Shariah compliant?

Nama's AAOIFI-style screen reads Krystal Biotech as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Krystal Biotech (KRYS)

Healthcare · Biotechnology · NASDAQ

Krystal Biotech (KRYS) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $8.92B, a trailing price-to-earnings ratio of 40.8 and a free-cash-flow yield of 2.1%. Over the most recent reported fiscal year, revenue grew 33.9% and free cash flow per share grew 57.4%. Nama's AI scorecard rates it Buy, 7.7 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Buy · 7.7/10

Clearly positive, short of the top band. As of Nov 7, 2026.

Momentum

Leading · +62.3% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-21.4%

How far the last close sits under the highest price of the past five years.

Market cap	$8.92B
Trailing P/E	40.8
Price / book	6.5
Price / sales	20.2
FCF yield	2.1%
Dividend yield	—
Gross margin	94.6%
Operating margin	44.9%
Net margin	54.8%
Revenue growth (YoY)	+33.9%
Revenue growth (3-yr annual)	—
EPS growth (YoY)	+62.7%
FCF/share growth (YoY)	+57.4%
Beta	0.5
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

KRYS earnings

Next report: Feb 16, 2027 (Q4 2026, EPS estimate $2.30). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 2, 2026	$2.05	$1.92	+6.8%	$127.34M
Q2 2026	Aug 3, 2026	$1.79	$1.91	-6.3%	$119.22M
Q1 2026	May 4, 2026	$1.83	$1.42	+28.9%	$116.36M
Q4 2025	Feb 17, 2026	$1.70	$1.61	+5.6%	$107.11M

KRYS analyst price target

Median target $380.00 from 9 analysts, ranging $284.00 – $474.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live KRYS data on Nama Insights →

KRYS FAQ

Is KRYS a buy?: Nama's AI scorecard currently rates Krystal Biotech Buy (7.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is KRYS's P/E ratio?: Krystal Biotech trades at a trailing price-to-earnings ratio of 40.8.
When does KRYS report earnings?: Krystal Biotech's next scheduled report is on Feb 16, 2027. Analysts expect EPS of $2.30.
What is the KRYS price target?: The median analyst price target from 9 analysts is $380.00, with a range of $284.00 – $474.00.
Is KRYS Shariah compliant?: Nama's AAOIFI-style screen reads Krystal Biotech as Not Shariah Compliant. At least one of the three ratios or the industry test failed.